BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1037 related articles for article (PubMed ID: 24954536)

  • 1. KRAS and YAP1 converge to regulate EMT and tumor survival.
    Shao DD; Xue W; Krall EB; Bhutkar A; Piccioni F; Wang X; Schinzel AC; Sood S; Rosenbluh J; Kim JW; Zwang Y; Roberts TM; Root DE; Jacks T; Hahn WC
    Cell; 2014 Jul; 158(1):171-84. PubMed ID: 24954536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAP1 takes over when oncogenic K-Ras slumbers.
    Greten FR
    Cell; 2014 Jul; 158(1):11-2. PubMed ID: 24995973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YAP1 and PRDM14 converge to promote cell survival and tumorigenesis.
    Kim M; Ly SH; Xie Y; Duronio GN; Ford-Roshon D; Hwang JH; Sulahian R; Rennhack JP; So J; Gjoerup O; Talamas JA; Grandclaudon M; Long HW; Doench JG; Sethi NS; Giannakis M; Hahn WC
    Dev Cell; 2022 Jan; 57(2):212-227.e8. PubMed ID: 34990589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer.
    Kapoor A; Yao W; Ying H; Hua S; Liewen A; Wang Q; Zhong Y; Wu CJ; Sadanandam A; Hu B; Chang Q; Chu GC; Al-Khalil R; Jiang S; Xia H; Fletcher-Sananikone E; Lim C; Horwitz GI; Viale A; Pettazzoni P; Sanchez N; Wang H; Protopopov A; Zhang J; Heffernan T; Johnson RL; Chin L; Wang YA; Draetta G; DePinho RA
    Cell; 2014 Jul; 158(1):185-197. PubMed ID: 24954535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YAP1 and TAZ Control Pancreatic Cancer Initiation in Mice by Direct Up-regulation of JAK-STAT3 Signaling.
    Gruber R; Panayiotou R; Nye E; Spencer-Dene B; Stamp G; Behrens A
    Gastroenterology; 2016 Sep; 151(3):526-39. PubMed ID: 27215660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma.
    Mohamed AD; Shah N; Hettmer S; Vargesson N; Wackerhage H
    Sci Rep; 2018 Oct; 8(1):15674. PubMed ID: 30353028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.
    Kitajima S; Asahina H; Chen T; Guo S; Quiceno LG; Cavanaugh JD; Merlino AA; Tange S; Terai H; Kim JW; Wang X; Zhou S; Xu M; Wang S; Zhu Z; Thai TC; Takahashi C; Wang Y; Neve R; Stinson S; Tamayo P; Watanabe H; Kirschmeier PT; Wong KK; Barbie DA
    Cancer Cell; 2018 Sep; 34(3):439-452.e6. PubMed ID: 30205046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.
    Edwards AC; Stalnecker CA; Jean Morales A; Taylor KE; Klomp JE; Klomp JA; Waters AM; Sudhakar N; Hallin J; Tang TT; Olson P; Post L; Christensen JG; Cox AD; Der CJ
    Cancer Res; 2023 Dec; 83(24):4112-4129. PubMed ID: 37934103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
    Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
    Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.
    Singh A; Sweeney MF; Yu M; Burger A; Greninger P; Benes C; Haber DA; Settleman J
    Cell; 2012 Feb; 148(4):639-50. PubMed ID: 22341439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
    Kharbanda A; Rajabi H; Jin C; Alam M; Wong KK; Kufe D
    Oncotarget; 2014 Oct; 5(19):8893-905. PubMed ID: 25245423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in
    Wu DW; Lin PL; Wang L; Huang CC; Lee H
    Theranostics; 2017; 7(5):1114-1132. PubMed ID: 28435452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zinc-Dependent Regulation of ZEB1 and YAP1 Coactivation Promotes Epithelial-Mesenchymal Transition Plasticity and Metastasis in Pancreatic Cancer.
    Liu M; Zhang Y; Yang J; Zhan H; Zhou Z; Jiang Y; Shi X; Fan X; Zhang J; Luo W; Fung KA; Xu C; Bronze MS; Houchen CW; Li M
    Gastroenterology; 2021 Apr; 160(5):1771-1783.e1. PubMed ID: 33421513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
    Steckel M; Molina-Arcas M; Weigelt B; Marani M; Warne PH; Kuznetsov H; Kelly G; Saunders B; Howell M; Downward J; Hancock DC
    Cell Res; 2012 Aug; 22(8):1227-45. PubMed ID: 22613949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.
    Vicent S; Chen R; Sayles LC; Lin C; Walker RG; Gillespie AK; Subramanian A; Hinkle G; Yang X; Saif S; Root DE; Huff V; Hahn WC; Sweet-Cordero EA
    J Clin Invest; 2010 Nov; 120(11):3940-52. PubMed ID: 20972333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GNAS
    Ideno N; Yamaguchi H; Ghosh B; Gupta S; Okumura T; Steffen DJ; Fisher CG; Wood LD; Singhi AD; Nakamura M; Gutkind JS; Maitra A
    Gastroenterology; 2018 Nov; 155(5):1593-1607.e12. PubMed ID: 30142336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical role for transcriptional repressor Snail2 in transformation by oncogenic RAS in colorectal carcinoma cells.
    Wang Y; Ngo VN; Marani M; Yang Y; Wright G; Staudt LM; Downward J
    Oncogene; 2010 Aug; 29(33):4658-70. PubMed ID: 20562906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-inducible factor 2α (HIF-2α) promotes colon cancer growth by potentiating Yes-associated protein 1 (YAP1) activity.
    Ma X; Zhang H; Xue X; Shah YM
    J Biol Chem; 2017 Oct; 292(41):17046-17056. PubMed ID: 28848049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes.
    Chun SY; Johnson C; Washburn JG; Cruz-Correa MR; Dang DT; Dang LH
    Mol Cancer; 2010 Nov; 9():293. PubMed ID: 21073737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.